Shots:

• The P-III study evaluate the efficacy, safety & immunogenicity of BCD-021 (q3w for 6 cycles) vs Avastin + paclitaxel & carboplatin in 357 patients with stage IIIB or IV nonsq. NSCLC across Russia, Belarus, Ukraine & India
• The results showed an equivalent efficacy when assessed as risk difference & risk ratio; ORR (34.6% & 33.8%) while 341 patients had 1 CT scan after initiation of treatment; patients with SD, CR or PR @18wks. were offered BCD-021 until disease progression, death, or unacceptable toxicity
• Additionally, baseline characteristics were balanced b/w BCD-021 and reference bevacizumab. The biosimilars will broaden the access of various populations to bevacizumab therapy

| Ref: Biocad  | Image: CPhl Online